Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)
Despite significant therapeutic advances, most patients with multiple myeloma (MM) eventually relapse and require successive lines of therapy, with progressively shorter remissions and increasing drug refractoriness [ 1 , 2 ]. Treatment patterns and outcomes of relapsed/refractory MM (RRMM) patients in Asia differ substantially from those reported in Western populations due to differences in drug availability, reimbursement, healthcare infrastructure, access to clinical trials, patient and carer preferences [ 3 ], and potentially disease biology [ 4 ]. Despite these important differences, real-world data describing treatment sequencing and outcomes across Asia remain limited. We therefore conducted a multinational and multiregional Asian Myeloma Network (AMN) study to characterize real-world treatment patterns and clinical outcomes in MM patients receiving second line (2 L), third line (3 L), and fourth line (4 L) therapy, to provide a benchmark for RRMM treatment management across Asia.
Authors
- Shuji Ozaki (ORCID: https://orcid.org/0000-0002-9808-0752)
- Cinnie Yentia Soekojo (ORCID: https://orcid.org/0000-0001-8376-8872)
- Ho‐Young Yhim (ORCID: https://orcid.org/0000-0002-1252-5336)
- Melinda Si Yun Tan (ORCID: https://orcid.org/0000-0003-1690-1447)
- Hiroyuki Takamatsu (ORCID: https://orcid.org/0000-0001-9515-0017)
- Hiroshi Handa (ORCID: https://orcid.org/0000-0001-6656-9521)
- Yeung‐Chul Mun (ORCID: https://orcid.org/0000-0002-1882-3983)
- Makoto Sasaki (ORCID: https://orcid.org/0000-0002-9360-5134)
- Juan Du (ORCID: https://orcid.org/0000-0003-2538-4007)
- Hirono Iriuchishima (ORCID: https://orcid.org/0000-0002-6970-9881)
- Wee Joo Chng (ORCID: https://orcid.org/0000-0003-2578-8335)
- Chandramouli Nagarajan (ORCID: https://orcid.org/0000-0001-5755-2226)
- Chieh‐Lin Jerry Teng (ORCID: https://orcid.org/0000-0001-9744-0368)
- Priti Bahety (ORCID: https://orcid.org/0000-0002-5556-970X)
- Tadao Ishida (ORCID: https://orcid.org/0000-0003-3219-3292)
- Shinsuke Iida (ORCID: https://orcid.org/0000-0002-4951-960X)
- Chihiro Shimazaki (ORCID: https://orcid.org/0000-0002-1006-7749)
- Kihyun Kım (ORCID: https://orcid.org/0000-0002-5878-8895)
- Xinhua Li (ORCID: https://orcid.org/0000-0003-2360-7553)
- Jong Heon Jung
- Chang‐Ki Min (ORCID: https://orcid.org/0000-0002-1940-0392)
- Karen Wong (ORCID: https://orcid.org/0000-0002-4864-4900)
- Wenming Chen (ORCID: https://orcid.org/0000-0001-6298-8489)
- Ho-Jin Shin
- Ling Cao
- Cheng-Shyong Chang
- Karen Tang
- Jae Hoon Lee
- Jeffrey Huang
- Sarah Burkhill
Institutions
- Gunma University (JP)
- Singapore General Hospital (SG)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Queen Mary Hospital (CN)
- Samsung Medical Center (KR)
- Tan Tock Seng Hospital (SG)
- Gachon University Gil Medical Center (KR)
- Taichung Veterans General Hospital (TW)
- Shanghai Changzheng Hospital (CN)
- Tokushima Prefectural Central Hospital (JP)
- National University Cancer Institute, Singapore (SG)
- Japanese Red Cross Medical Center (JP)
- Kanazawa University Hospital (JP)
- Nagoya City University Hospital (JP)
- Pusan National University Hospital (KR)
- National Cancer Center (KR)
- Chang Bing Show Chwan Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
- Jeonbuk National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Juntendo University Hospital (JP)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Singapore Clinical Research Institute (SG)
- Okinawa Miyako Hospital (JP)
- Kasukabe Medical Center (JP)
- Itabashi Chuo Medical Center (JP)
- Ewha Womans University Mokdong Hospital (KR)
- Kyoto Kuramaguchi Medical Center (JP)
- University of Hong Kong (HK)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2026-11-11
- DOI
- https://doi.org/10.1038/s41408-026-01641-5
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00